Pyronaridine-d4 (tetraphosphate)

• Description:

  Pyronaridine-d4 (tetraphosphate) is the deuterium labeled Pyronaridine tetraphosphate[1]. Pyronaridine tetraphosphate is an orally active Mannich base anti-malarial agent. Pyronaridine tetraphosphate is active against P. falciparum and Echinococcus granulosus infection[2][3].

• UNSPSC:

  12352005

• Target:

  Parasite

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Purity:

  97.00

• Solubility:

  H2O : 25 mg/mL (ultrasonic; warming)

• Smiles:

  O=P (O) (O) O.ClC1=CC2=C (C=C1) C (NC3=CC (C ([2H]) ([2H]) N4CCCC4) =C (C (C ([2H]) ([2H]) N5CCCC5) =C3) O) =C6C (C=CC (OC) =N6) =N2.O=P (O) (O) O.O=P (O) (O) O.O=P (O) (O) O

• Molecular Formula:

  C29H40D4ClN5O18P4

• Molecular Weight:

  914.06

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Vivas L, et al. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Trop. 2008 Mar;105 (3) :222-8.|[3]Jun Li, et al. Old drug repurposing for neglected disease: Pyronaridine as a promising candidate for the treatment of Echinococcus granulosus infections. EBioMedicine. 2020 Apr;54:102711.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  1186026-25-4